Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
Ce dossier présente un ensemble d'articles concernant la biologie et le traitement par immunothérapie de cancers hématologiques
The outcome of B-cell precursor acute lymphoblastic leukemia (ALL) is different in children and adults, with overall survival (OS) rates at 5 years ranging from 90% to 45%.1,2 Significant needs also remain unmet in patients with B-cell non-Hodgkin lymphoma (NHL), with rates of refractory disease up to 20% according to histology in the rituximab era.3-5 In both ALL and NHL, many patients fail not only front-line but also salvage treatments, including allogeneic hematopoietic stem cell transplantation (alloHSCT). The therapeutic scenario for these patients with relapsed/refractory (R/R) disease is evolving, and immunotherapy is at the forefront. It took many years to move from the first to the current generation of bispecific antibodies that are changing the therapeutic landscape of acute leukemias and lymphomas.6,7 Today the ability to produce recombinant antibodies allows the generation of bispecific antibodies with defined pharmacological properties (Fig 1).8 Herein, we have reviewed the clinical development of antibodies designed to redirect the cytotoxic potential of nonantigen-specific T cells on specific antigens, such as CD19 and CD20 expressed on the cell surface of precursor and mature B lymphocytes.